Pricing Log in Create free account
Tuesday 13 October 2026 Export AUTL’s income statement to Excel — free account

Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.66 0.08 −4.60%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 9.63%

Capital & Financial Ratios $m

Market Cap 463.12
Revenue 117.39
Net Income (280.16)
Free Cash Flow (232.73)
Net Debt (125.40)
Current Ratio 4.89 (at or above 1.5: strong)
Debt/Equity 1.04
P/E ratio 0.00
Fwd P/E (1.69) (negative: loss-making)
P/S ratio 3.95
P/B ratio 6.19 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 27.48% (at or above 15%: strong)
Next Y EPS Growth 20.13% (at or above 15%: strong)
Next Y revenue growth 98.71% (at or above 10%: strong)
Next 5Y EPS Growth 26.28% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 35.6×; over the ten years it ranged from −27.4× in 2023 to 731× in 2018.
P/S against its own 10 years 1.28%
10-year low 10-year high
P/B against its own 10 years 93.87%
10-year low 10-year high
EV/Sales against its own 10 years 13.62%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 240 589 302 203
Receivables — 0 24 44
Inventory — 4 33 33
Other — — — —
275 661 436 336
2023 2024 2025 Q'26
Payables 0 2 3 1
ST’ Debt — — — —
Other — 4 10 13
45 61 73 69

Compound Annual Growth %

10y 5y 3y
Sales — 113.11% 128.01%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 2.25% (3.24%) (15.83%)

Revenue $m

Mar Jun Sep Dec Year
’26 26 46 — — —
’25 9 21 21 24 75
’24 10 — — 0 10
’23 1 — 0 0 2
’22 0 — 2 4 6
’21 0 2 0 0 2
’20 0 0 1 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (65) (25) — — —
’25 (76) (73) (68) (67) (284)
’24 (41) (51) (77) (38) (206)
’23 (42) (38) (40) (25) (146)
’22 (35) (31) (32) (15) (112)
’21 (37) (37) (35) (9) (118)
’20 (24) (27) (39) (28) (118)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (68) (26) — — —
’25 (84) (80) (80) (66) (311)
’24 (41) (52) (86) (62) (241)
’23 (46) (43) (42) (26) (157)
’22 (36) (33) (39) (15) (123)
’21 (39) (38) (39) (11) (127)
’20 (27) (29) (43) (33) (132)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.27) (0.15) — — —
’25 (0.26) (0.18) (0.30) (0.34) (1.08)
’24 (0.24) (0.22) (0.31) (0.09) (0.86)
’23 (0.23) (0.26) (0.26) (0.44) (1.20)
’22 (0.41) (0.46) (0.47) (0.23) (1.57)
’21 (0.53) (0.47) (0.47) (0.51) (1.97)
’20 (0.60) (0.62) (0.72) (0.82) (2.76)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 19.17 9.50 3.00 4.60 1.60 1.61 2.07 1.11

Analyst estimates 2026–2028

Powerpack
High — — 53.24 36.00 17.19 9.98 5.59 6.94 7.45 2.80
People
People Employees — 126 166 290 376 324 399 463 647 752
Revenue/emp, $m 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.02 0.10
Income, $m
Income, $m Revenue 2 2 1 3 2 2 6 2 10 75
Gross margin, % 100.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 (12.52) (27.83)
EBT (23) (23) (52) (139) (166) (166) (149) (208) (219) (286)
EBT margin, % (1,380.98) 0.00 0.00 (4,780.19) (9,694.29) (7,123.95) (2,335.96) (12,273.38) (2,165.36) (378.78)
Net income 0 20 0 (124) (142) (142) (149) (208) (221) (288)
Depreciation 0 1 2 5 6 8 7 7 8 10
Per share, $
Per share, $ Revenue 0.04 0.00 0.00 0.07 0.03 0.03 0.07 0.01 0.04 0.28
Earnings (0.31) (0.49) (1.42) (2.88) (2.76) (1.97) (1.57) (1.20) (0.86) (1.08)
Cash flow (0.25) 0.07 (1.00) (2.36) (2.28) (1.64) (1.18) (0.84) (0.81) (1.07)
Capex 0.00 (0.06) 0.00 (0.43) (0.28) (0.12) (0.11) (0.06) (0.14) (0.10)
Free cash flow (0.25) 0.01 (1.00) (2.79) (2.57) (1.76) (1.30) (0.90) (0.94) (1.17)
Book value 3.55 (0.08) 7.37 5.92 4.07 4.35 3.14 0.64 1.67 0.67
Shares, m 40 51 32 43 52 72 95 174 255 266
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 195.49 268.76 160.56 27.16 215.42 56.97 7.03
P/B 5.05 5.05 4.70 2.23 2.19 1.19 0.59 10.67 1.40 2.97
EV/Sales 0.00 0.00 0.00 130.93 208.41 34.33 (28.43) 180.58 5.68 3.90
EV/FCF 0.00 0.00 (18.97) (3.16) (2.68) (0.63) 1.50 (6.34) (0.25) (0.91)
Cash, $m
Cash, $m Operating cash flow (10) 3 (32) (101) (118) (118) (112) (146) (206) (284)
Capex (2) (3) (10) (19) (15) (9) (11) (11) (35) (27)
Free cash flow (10) 0 (32) (120) (132) (127) (123) (157) (241) (311)
Balance, $m
Balance, $m Working capital 137 0 212 224 163 318 379 231 600 362
Total debt — 0 0 24 51 17 19 48 50 —
Net debt (137) (137) (217) (188) (104) (294) (364) (192) (540) (302)
Shareholders’ equity 143 (4) 233 255 210 313 299 111 427 178
Returns, %
Returns, % ROA (13.27) (58.09) (16.97) (44.41) (47.54) (40.61) (33.23) (48.14) (38.11) (41.92)
ROIC (83.69) 0.00 0.00 (136.01) (98.66) (537.42) 0.00 0.00 0.00 0.00
ROE (41.66) (64.50) (18.34) (50.81) (61.13) (54.30) (48.64) (101.61) (81.91) (94.98)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026

Charts ten years each

Autolus Therapeutics PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ARVN Arvinas, Inc. $499.6M 57.3× — (loss-making) +1,014.73% (above 0%: growing) n/m +49.79% (above 0%: growing) 96.40% 65.72% Compare
EPRX Eupraxia Pharmaceuticals Inc. $491.7M — (loss-making) — — n/m −56.41% (below 0%: shrinking) — 0.00% Compare
MPLT MapLight Therapeutics, Inc. $490.7M — (loss-making) — — n/m −31.91% (below 0%: shrinking) — 0.00% Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $481.8M — (loss-making) — (loss-making) +118.37% (above 0%: growing) n/m +67.55% (above 0%: growing) 55.20% (95.95%)
OVID Ovid Therapeutics $480.4M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
ASMB Assembly Biosciences, Inc. $479.1M 22.3× — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%) Compare
YDES YD Bio Limited $476.8M — — — — — — — Compare
RZLT Rezolute, Inc. $471.1M — (loss-making) — — n/m +40.23% (above 0%: growing) 0.00% 0.00% Compare
ENTX Entera Bio Ltd. $462.4M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $479.8M — — +331.93% — −31.91% 96.40% 0.00%

All 614 Biotechnology stocks →

Autolus Therapeutics PLC Sponsored ADR (AUTL) key facts

  • Autolus Therapeutics PLC Sponsored ADR (AUTL) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 12, 2026, AUTL traded at $1.74, a market capitalization of $463.1 million.
  • Return on equity was −95.0% and debt-to-equity 1.04.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.17 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.

Autolus Therapeutics PLC Sponsored ADR (AUTL) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/AUTL · Data as of Sep 28, 2026 · For information only; not investment advice. · © 2026 stockrow.com